Neoadjuvant therapy for NSCLC: From monotherapy to precision combination therapy
- 9 July 2026
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 225, 105472
Abstract
No abstract availableKeywords
Funding Information
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
This publication has 102 references indexed in Scilit:
- Efficacy of radiolabelled PD-L1-targeted nanobody in predicting and evaluating the combined immunotherapy and chemotherapy for resectable non-small cell lung cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2025
- Functional and phenotypic changes in natural killer cells expressing immune checkpoint receptors PD-1, CTLA-4, LAG-3, and TIGIT in non-small cell lung cancer: the comparative analysis of tumor microenvironment, peripheral venous blood, and tumor-draining veinsImmunologic Research, 2024
- Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non–Small Cell Lung CancerJAMA Oncology, 2024
- Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trialCancer Cell, 2024
- Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLCAnnals of Oncology, 2024
- Neoadjuvant Targeted Therapy in Non–Small Cell Lung Cancer and Its Impact on Surgical OutcomesAnnals of Thoracic Surgery Short Reports, 2022
- Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation studyAnnals of Oncology, 2022
- Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non–small-cell Lung Cancer: SQUAT trial (WJOG 12119L)Clinical Lung Cancer, 2021
- Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020Cancer Communications, 2021
- Osimertinib: First Global ApprovalDrugs, 2016